The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells

PURPOSE: As radiation therapy is widely used for the management of pancreatic cancer, identifying novel targets to improve the radiosensitivity of cancer cells is beneficial. Rosiglitazone, a specific peroxisome proliferator-activated receptor γ (PPARγ) agonist, has an inhibitory effect on various t...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhenyu, Shen, Wenhao, Li, Xugang, Feng, Yang, Qian, Kun, Wang, Gaoren, Gao, Yiying, Xu, Xiaohui, Zhang, Shuyu, Yue, Ling, Cao, Jianping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410396/
https://www.ncbi.nlm.nih.gov/pubmed/32801648
http://dx.doi.org/10.2147/DDDT.S242557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410396/
https://www.ncbi.nlm.nih.gov/pubmed/32801648
http://dx.doi.org/10.2147/DDDT.S242557

Ejemplares similares